marketcap
Facebook
Twitter
Telegram
Report an ErrorAnnual report 2023
added 11-18-2024
Aeglea BioTherapeutics Balance Sheet 2011-2024 | AGLE
Annual Balance Sheet Aeglea BioTherapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-30.2 M | -14.7 M | -84.6 M | -14.2 M | -22.5 M | -12.8 M | -47.7 M | -29.3 M | -2.62 M | -4.6 M | - | - | |
Long Term Debt |
- | 4 M | 16 K | 5.13 M | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
- | 625 K | 436 K | 319 K | 351 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 4.74 M | 72 K | 111 K | 132 K | 27 K | - | - | - | - |
Total Current Liabilities |
32 M | 14.7 M | 20.1 M | 16.4 M | 18.4 M | 10.2 M | 5.63 M | 3.96 M | - | - | - | - | - |
Total Liabilities |
73.3 M | 20.8 M | 26 M | 21.8 M | 23.1 M | 10.3 M | 5.74 M | 4.1 M | 2.55 M | 1.06 M | 1.41 M | - | - |
Deferred Revenue |
- | 517 K | 2.36 M | - | - | - | 20 K | 71 K | - | - | - | - | - |
Retained Earnings |
-764 M | -426 M | -342 M | -276 M | -195 M | -117 M | -72.5 M | -45.3 M | -23.6 M | -12.3 M | -1.94 M | - | - |
Total Assets |
342 M | 71.1 M | 110 M | 162 M | 83.2 M | 77.7 M | 56.1 M | 67.1 M | 38.7 M | 2.93 M | 4.6 M | - | - |
Cash and Cash Equivalents |
189 M | 34.9 M | 17 M | 90.1 M | 19.3 M | 22.5 M | 12.8 M | 47.7 M | 29.3 M | 2.62 M | - | - | - |
Book Value |
269 M | 50.3 M | 83.9 M | 140 M | 60.1 M | 67.4 M | 50.3 M | 63 M | 36.1 M | 1.87 M | 3.18 M | - | - |
Total Shareholders Equity |
184 M | 50.3 M | 83.9 M | 140 M | 60.1 M | 67.4 M | 50.3 M | 63 M | -22.2 M | -11.5 M | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Aeglea BioTherapeutics
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | - | - | 3.82 M | 4 M | 4.16 M | - | 4.47 M | 4.61 M | 4.75 M | 4.88 M | 5.01 M | 45 K | 5.13 M | 5.13 M | 5.13 M | 31 K | 38 K | 45 K | 52 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
93.7 M | 61.7 M | 81.9 M | 73.3 M | 65.6 M | 254 M | 18.8 M | 20.8 M | 24 M | - | 21.5 M | 26 M | 27 M | 28 M | 39.9 M | 21.8 M | 21.8 M | 21.8 M | 21.8 M | 23.1 M | 23.1 M | 23.1 M | 23.1 M | 10.3 M | 10.3 M | 10.3 M | 10.3 M | 5.74 M | 5.74 M | 5.74 M | 5.74 M | 4.1 M | 4.1 M | 4.1 M | 4.1 M | 2.55 M | 2.55 M | 2.55 M | 2.55 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | 930 K | 302 K | 517 K | 505 K | - | 2.07 M | 2.36 M | 4.79 M | 5.53 M | 19.2 M | - | - | - | - | - | - | - | - | - | - | - | - | 20 K | 20 K | 20 K | 20 K | 71 K | 71 K | 71 K | 71 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-916 M | -847 M | -808 M | -764 M | -701 M | -661 M | -444 M | -426 M | -407 M | - | -366 M | -342 M | -321 M | -301 M | -294 M | -276 M | -276 M | -276 M | -276 M | -195 M | -195 M | -195 M | -195 M | -117 M | -117 M | -117 M | -117 M | -72.5 M | -72.5 M | -72.5 M | -72.5 M | -45.3 M | -45.3 M | -45.3 M | -45.3 M | -23.6 M | -23.6 M | -23.6 M | -23.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
421 M | 436 M | 488 M | 342 M | 207 M | 244 M | 52.5 M | 71.1 M | 91.6 M | - | 83.2 M | 110 M | 129 M | 147 M | 164 M | 162 M | 162 M | 162 M | 162 M | 83.2 M | 83.2 M | 83.2 M | 83.2 M | 77.7 M | 77.7 M | 77.7 M | 77.7 M | 56.1 M | 56.1 M | 56.1 M | 56.1 M | 67.1 M | 67.1 M | 67.1 M | 67.1 M | 38.7 M | 38.7 M | 38.7 M | 38.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
71.6 M | 45.1 M | 228 M | 189 M | 90.6 M | 235 M | 36.6 M | 34.9 M | 40.5 M | - | 14.6 M | 15.1 M | 24.7 M | 34.8 M | 80.2 M | 90.1 M | 90.1 M | 90.1 M | 90.1 M | 19.3 M | 19.3 M | 19.3 M | 19.3 M | 22.5 M | 22.5 M | 22.5 M | 22.5 M | 12.8 M | 12.8 M | 12.8 M | 12.8 M | 47.7 M | 47.7 M | 47.7 M | 47.7 M | 29.3 M | 29.3 M | 29.3 M | 29.3 M | 2.62 M | - | - | - | 4.6 M | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
327 M | 374 M | 406 M | 269 M | 142 M | -10 M | 33.7 M | 50.3 M | 67.6 M | - | 61.7 M | 83.9 M | 102 M | 119 M | 124 M | 140 M | 140 M | 140 M | 140 M | 60.1 M | 60.1 M | 60.1 M | 60.1 M | 67.4 M | 67.4 M | 67.4 M | 67.4 M | 50.3 M | 50.3 M | 50.3 M | 50.3 M | 63 M | 63 M | 63 M | 63 M | 36.1 M | 36.1 M | 36.1 M | 36.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
327 M | 374 M | 152 M | 184 M | -245 M | -207 M | 33.7 M | 50.3 M | 67.6 M | 84.2 M | 61.7 M | 83.9 M | 102 M | 119 M | 124 M | 140 M | 140 M | 140 M | 140 M | 60.1 M | 60.1 M | 60.1 M | 60.1 M | 67.4 M | 67.4 M | 67.4 M | 67.4 M | 50.3 M | 50.3 M | 50.3 M | 50.3 M | 63 M | 63 M | 63 M | 63 M | -22.2 M | -22.2 M | -22.2 M | -22.2 M | -11.5 M | - | - | - | -1.27 M | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency